Etentamig
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Arms / Cohorts
Experimental Part 1, Arm A:Etentamig (ABBV-383) + Pomalidomide + Dexamethasone
Accepting patients
Experimental Part 1, Arm B:Etentamig (ABBV-383) + Lenalidomide + Dexamethasone
Accepting patients
Experimental Part 1, Arm C:Etentamig (ABBV-383) + Daratumumab + Dexamethasone
Accepting patients
Experimental Part 2, Arm E:Etentamig (ABBV-383) + Pomalidomide + Dexamethasone
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.